Continued to advance three clinical programs in immune-mediated diseases: The Phase 3 ONWARD program for ESK-001 in moderate-to-severe plaque psoriasis consists of two parallel 24-week global Phase 3 ...
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback